The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
EHA 2019 | Myeloma XI subgroup analysis of KCRd induction by molecular risk
To view this video in other languages, please play the video and click on the settings icon. Click on “subtitles/CC”, followed by “auto translate”, and then select your chosen language from the drop-down menu.
At the 24th Congress of the European Hematology Association (EHA), Charlotte Pawlyn from the Institute of Cancer Research, London, UK, presents a subgroup analysis of carfilzomib, cyclophosphamide, lenalidomide, and dexamethasone (KCRd) induction by molecular risk from the Myeloma XI study.
Dr. Pawlyn introduces the Myeloma XI trial which evaluated more than 4000 newly diagnosed transplant eligible patients with MM in 110 National Health Service (NHS) centers. The subgroup analysis of a patient population with genetic mutations showed similarly superior progression-free survival (PFS) with quadruplet, rather than triplet, therapy.
Myeloma XI subgroup analysis of KCRd induction by molecular risk